Valneva Seeks Investor Reset Amid Legal and Clinical Headwinds

Valneva pivots to Brazil for its Chikungunya vaccine after U.S. withdrawal, as legal probes and a failed Lyme trial pressure the stock.

Valneva's management team is preparing a crucial presentation for institutional investors this week, aiming to shift the narrative away from a recent clinical setback and looming U.S. legal probes. The French vaccine developer’s stock has plummeted over 40% in the past month, a stark reflection of market panic following mixed results from a key late-stage trial.

The focal point of the Amsterdam conference, which begins on April 15, will be the company's Chikungunya vaccine, IXCHIQ. Valneva is highlighting progress in Brazil, where the vaccine received approval in April 2025. A pilot immunization campaign in collaboration with Instituto Butantan has already vaccinated more than 12,000 individuals, with Valneva donating up to 500,000 doses for the program. This international push is a strategic necessity after the company voluntarily withdrew its U.S. applications for IXCHIQ in January 2026. The Food and Drug Administration had previously suspended the license while investigating reports of severe adverse events.

This pivot comes as Valneva faces significant legal pressure. Since early April, U.S. law firms, including Pomerantz LLP, have been investigating potential securities fraud or other unlawful business practices by the company and its executives. The probe was triggered by the Phase 3 trial for the Lyme disease vaccine candidate, PF-07307405, developed with Pfizer. While the partners presented the data positively, the vaccine officially missed its primary endpoint due to an insufficient number of disease cases, creating a discrepancy that spooked investors. The share price currently sits at 2.70 euros.

Despite the turbulence, partner Pfizer remains committed to the Lyme vaccine project. The pharmaceutical giant still plans to submit regulatory applications for the candidate in the second half of 2026. Financially, Valneva appears to have some breathing room for now. The company's cash reserves stand at approximately 110 million euros, and its cash-burn rate has been reduced by 21%. However, analysts have removed projected U.S. revenue for IXCHIQ from their models and anticipate only modest demand in Europe.

The upcoming investor meeting marks the first direct engagement with major shareholders since the stock crash and subsequent legal announcements. It will be followed shortly by a concrete financial update. Valneva is scheduled to release its first-quarter 2026 results on May 7, providing a detailed look at how the U.S. market withdrawal and recent clinical developments have impacted its balance sheet.